Recurrent astrocytoma in a child: A report of cytogenetics and TP53 gene mutation screening

被引:0
|
作者
Dam, A
Fock, JM
Hayes, VM
Molenaar, WM
van den Berg, E
机构
[1] Univ Groningen Hosp, Dept Pathol, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Child Neurol, NL-9713 GZ Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Med Genet, NL-9713 GZ Groningen, Netherlands
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An 8-year-old girl presented with a cerebral tumor and 3 recurrences within 15 months, The primary tumor was a low-grade astrocytoma, but the recurrences showed progressively malignant phenotypes with increasing mitotic activity and MIB-1 labeling indices. Radiotherapy was given between the first and the second recurrences. Cytogenetic analysis of the first and the second recurrences showed abnormal karyotypes. There seemed to be 2 common breakpoints in these 2 recurrences. TP53 gene mutation screening, using comprehensive denaturing gradient gel electrophoresis, revealed among others a possibly causative mutation of exon 5 in 3 of 4 tumor samples, The meaning of TP53 mutations in low-grade astrocytomas is still unclear, but the highly abnormal karyotypes, which are unusual in these tumors, probably provide genetic evidence for the unexpected aggressive behavior of the tumor in this patient.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [41] EGFR gene amplification and TP53 mutation gene expression profiles in glioblastomas.
    Louis, DN
    Pomeroy, SL
    Golub, TR
    Nutt, CL
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (05): : 542 - 542
  • [42] Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway
    Saba, Karim H.
    Difilippo, Valeria
    Kovac, Michal
    Cornmark, Louise
    Magnusson, Linda
    Nilsson, Jenny
    van den Bos, Hilda
    Spierings, Diana C. J.
    Bidgoli, Mahtab
    Jonson, Tord
    Sumathi, Vaiyapuri P.
    Brosjoe, Otte
    Staaf, Johan
    Foijer, Floris
    Styring, Emelie
    Nathrath, Michaela
    Baumhoer, Daniel
    Nord, Karolin H.
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 147 - 160
  • [43] TP53 overexpression in recurrent endometrial carcinoma
    Pijnenborg, JMA
    van de Broek, L
    de Veen, GCD
    Roemen, GMJM
    de Haan, J
    van Engeland, M
    Voncken, JW
    Groothuis, PG
    GYNECOLOGIC ONCOLOGY, 2006, 100 (02) : 397 - 404
  • [44] Clinical significance of TP53 mutation in myeloma
    Chng, W. J.
    Price-Troska, T.
    Gonzalez-Paz, N.
    Van Wier, S.
    Jacobus, S.
    Blood, E.
    Henderson, K.
    Oken, M.
    Van Ness, B.
    Greipp, P.
    Rajkumar, S. V.
    Fonseca, R.
    LEUKEMIA, 2007, 21 (03) : 582 - 584
  • [45] TP53 mutation in mucinous carcinoma of the breast
    Di Palma, S
    Lavarino, C
    Oggionni, M
    Pilotti, S
    HISTOPATHOLOGY, 1999, 34 (06) : 559 - 560
  • [46] Sarcomas in TP53 germline mutation carriers
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    CANCER RESEARCH, 2011, 71
  • [47] MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
    Floris H. Groenendijk
    Walter Taal
    Hendrikus J. Dubbink
    Cathleen R. Haarloo
    Mathilde C. Kouwenhoven
    Martin J. van den Bent
    Johan M. Kros
    Winand N. M. Dinjens
    Journal of Neuro-Oncology, 2011, 101 : 405 - 417
  • [48] MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
    Groenendijk, Floris H.
    Taal, Walter
    Dubbink, Hendrikus J.
    Haarloo, Cathleen R.
    Kouwenhoven, Mathilde C.
    van den Bent, Martin J.
    Kros, Johan M.
    Dinjens, Winand N. M.
    JOURNAL OF NEURO-ONCOLOGY, 2011, 101 (03) : 405 - 417
  • [49] TP53 mutation is rare in primary myelofibrosis
    Greaves, Wesley O.
    Verma, Shalini
    Bisrat, Tigist
    Strati, Paolo
    Rahimi, Hamed
    Paladugu, Abhaya V.
    Luthra, Rajyalakshmi
    Patel, Keyur P.
    Medeiros, L. Jeff Rey
    Yao, Hui
    Pierce, Sherry
    Bueso-Ramos, Carlos E.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1552 - 1552
  • [50] Clinical significance of TP53 mutation in myeloma
    W J Chng
    T Price-Troska
    N Gonzalez-Paz
    S Van Wier
    S Jacobus
    E Blood
    K Henderson
    M Oken
    B Van Ness
    P Greipp
    S V Rajkumar
    R Fonseca
    Leukemia, 2007, 21 : 582 - 584